

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandra, Virginia 22313-1450
www.mpto.gov

				•
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		<del></del>
10/034,819	12/27/2001		ATTORNEY DOCKET NO.	CONFIRMATION NO.
		Atli Thorarensen	00494.US1	1479
25533 7	590 09/30/2003			
PHARMACL	A & UPJOHN			
301 HENRIETTA ST			EXAMINER	
0228-32-LAW KALAMAZOO, MI 49007			LAMBKIN, DEBORAH C	
	, mi 47007		ART UNIT	PAPER NUMBER
			1626	-
			DATE MAILED: 09/30/2003	5
•				

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summan	10/034,819	THORARENSEN, ATLI				
Office Action Summary	Examiner	Art Unit				
	Deborah C Lambkin	1626				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1) Responsive to communication(s) filed on <u>04 November 2002</u> .						
2a)☐ This action is <b>FINAL</b> . 2b)⊠	This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims						
4) Claim(s) 1-17 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-17</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.  Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
14)☐ Acknowledgment is made of a claim for dom						
a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)				
J.S. Patent and Trademark Office PTOL-326 (Rev. 04-01) Offic	e Action Summary	Part of Paper No. 5				

Art Unit: 1626

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Haughan et al (US 5,792,774).

Haughan et al teach a genus of quinolones compounds which are useful for treating viral infections (col.4, lines 24-30), wherein when X is (CR9R10)2Y, R9R10 being H, Y is O, R1 is aryl substituted with halo, n is 1, Q is S, R3 and R5 is H and R4 is alkyl opt. sub with alkoxy or OH, are embrased by the instant genus. In addition, Haughan et al also teaches intermediates wherein removal of the protecting group is conventional in the art (col.4, lines 52-63), hence the obviousness of the instant intermediate.

There is nothing unobvious in choosing a species from a prior art genus, motivation being that said species would be expected to possess the same or similar properties as their exemplified counterparts, absent some unobvious or unexpected results. Furthermore, upon analysis of the instant claims and that of the prior art genus in question using In re Baird, it is determined that there is ample motivation from the examples to arrive at applicant compounds for treating viral infections.

No unobvious or unexpected results are seen.

Art Unit: 1626

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deborah C Lambkin whose telephone number is 703-308-4522. The examiner can normally be reached on 9.00-5.30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on 703-308-4537. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

DEBORAH C. LAMBKIN PRIMARY EXAMINER

\*\*\*